Bookmark with More


Visit the website

Cycloscope™ is an exclusive product line for cell DNA content studies by flow cytometry.

The detection of DNA ploidies and the study of cell cycle phases provide relevant clinical information for prognostic, evaluation and follow-up of patients with solid tumors or hematological malignancies. It has been proved that DNA ploidy is characteristic of malignant neoplasm for some type of diseases. Depending on the type of disease DNA ploidy can be associated with better or worse prognosis. Besides, a high proliferative rate of tumor cells is a condition usually associated to poor clinical outcomes and used for the evaluation of disease progression.

Cycloscope™ main advantage is that it can estimate cell DNA contents on tumor cells combined with their specific immunophenotype identification in a single tube.

Cycloscope™ kits include a specific monoclonal antibody pool to identify neoplasic cells and a ready-to-use DNA labeling solution. Cytognos offers several versions of this reagent:

  • Cycloscope™ MM: useful for the evaluation of DNA plasma cell content in Multiple Myeloma (MM) and Monoclonal Gammopathies of Undetermined Significance (MGUS) samples.
  • Cycloscope™ B-ALL: suitable for the evaluation of DNA content on neoplasic B-cell precursors in B lineage Acute Lymphoblastic Leukemia (B-ALL) samples.
  • Cycloscope™ NHL: designed to determine DNA content on neoplasic B-cells in B-lineage, Non Hodgkin Lymphoma (B-NHL) and other B-cell Chronic Lymphoproliferative Diseases (B-CLPD) samples.
  • Cycloscope™ SBC: developed for the screening of DNA content on epithelial cells of bladder cancer urine samples.
  • Cycloscope™ Reagent: ready-to-use DNA labeling solution (propidium iodide, permeabilization reagents and RNase) with an erythrocyte lysing solution.
  • DNA Labeling Solution: ready-to-use solution that contains propidium iodide, permeabilization reagents and RNase.